AIGH Capital Management LLC Has $10.77 Million Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

AIGH Capital Management LLC lifted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 82.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,438,109 shares of the company's stock after buying an additional 649,495 shares during the period. Zevra Therapeutics comprises 4.5% of AIGH Capital Management LLC's holdings, making the stock its 6th largest position. AIGH Capital Management LLC owned approximately 2.63% of Zevra Therapeutics worth $10,771,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Woodline Partners LP lifted its holdings in Zevra Therapeutics by 2.2% in the fourth quarter. Woodline Partners LP now owns 4,139,593 shares of the company's stock valued at $34,524,000 after buying an additional 90,940 shares during the period. Adage Capital Partners GP L.L.C. increased its position in Zevra Therapeutics by 462.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock valued at $30,441,000 after buying an additional 3,001,000 shares in the last quarter. Vanguard Group Inc. increased its position in Zevra Therapeutics by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company's stock valued at $23,554,000 after buying an additional 68,151 shares in the last quarter. Altium Capital Management LLC raised its holdings in shares of Zevra Therapeutics by 8.8% in the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock worth $15,429,000 after acquiring an additional 150,000 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Zevra Therapeutics by 13.8% in the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock worth $9,912,000 after acquiring an additional 144,256 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA traded down $0.03 during mid-day trading on Tuesday, reaching $11.70. 212,929 shares of the company were exchanged, compared to its average volume of 737,785. Zevra Therapeutics, Inc. has a 52 week low of $5.45 and a 52 week high of $13.16. The company has a quick ratio of 2.93, a current ratio of 3.02 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $639.76 million, a PE ratio of -6.16 and a beta of 1.97. The company's 50 day moving average price is $9.54 and its 200 day moving average price is $8.35.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The company had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same period in the previous year, the firm posted ($0.40) EPS. Sell-side analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ZVRA. HC Wainwright began coverage on shares of Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 target price on the stock. Cantor Fitzgerald increased their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Finally, Wall Street Zen downgraded shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Sunday. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $23.71.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

Want to see what other hedge funds are holding ZVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.